A look at Celgene
Celgene (CELG) is one of the leading biopharmaceutical companies, with headquarters in New Jersey. Celgene’s product portfolio includes drugs for the treatment of cancer and inflammatory diseases.
The above chart compares Celgene’s revenues and EPS (earnings per share) since 1Q16 and estimates for 1Q18.
Celgene stock fell 15% in 1Q18 and has fallen 15.2% year-to-date as of April 6, 2018.
Wall Street analysts estimate that Celgene (CELG) stock has the potential to return 31.6% over the next 12 months. Analysts’ recommendations show a 12-month target price of $116.48 per share compared to the last price of $86.95 per share as of April 6, 2018.
There are 31 analysts tracking Celgene stock. Eight of them recommend a “strong buy,” nine recommend a “buy,” 13 recommend a “hold,” and one recommends a “sell.” The consensus rating for Celgene stands at 2.2, which represents a “strong buy” for both momentum investors and long-term growth investors.
Analysts’ revenue estimates
Celgene revenues are driven mainly by the strong performances of key products, including Revlimid, Pomalyst, and Vidaza.
Wall Street analysts estimate revenues of $3.5 billion in 1Q18, a 16.8% growth compared to 1Q17, and EPS of $1.96.
The PowerShares Dynamic Pharmaceuticals ETF (PJP) holds 4.9% of its total investments in Celgene (CELG), 4.9% in Bristol-Myers Squibb (BMY), 5.2% in Pfizer (PFE), and 5.3% in Abbott Laboratories (ABT).
Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look.